GSK Stretches into Neuro with Muna Collaboration for Alzheimer's Amid Multiple High-Value Deals

GSK has forged a strategic partnership with Muna Therapeutics, a Danish biotech firm, to advance the treatment of Alzheimer's disease. This collaboration grants GSK access to Muna’s innovative MiND-MAP platform, which applies single-cell spatial multi-omics to dissect disease mechanisms via postmortem brain samples[1]. Muna will focus on identifying and validating therapy targets, while GSK will spearhead the drug development and commercialization efforts. The financial framework includes an upfront payment of €33.5 million to Muna, with additional potential milestone earnings of up to €140 million per target, alongside tiered royalties on future sales[3]. This partnership exemplifies GSK’s strategic shift back into neuroscience and signifies its ambitions to bolster drug discovery in neurodegenerative diseases[2].